Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cantuzumab mertansine, a maytansinoid immunoconjugate directed to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study.
Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, Takimoto C, Smith L, de Bono J, Schwartz G, Mays T, Jonak ZL, Johnson R, DeWitte M, Martino H, Audette C, Maes K, Chari RV, Lambert JM, Rowinsky EK. Tolcher AW, et al. Among authors: dewitte m. J Clin Oncol. 2003 Jan 15;21(2):211-22. doi: 10.1200/JCO.2003.05.137. J Clin Oncol. 2003. PMID: 12525512 Clinical Trial.
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF, Chao D, Hall K, Lee C, Timotheadou E, Charles K, Ahern R, King DM, Eisen T, Corringham R, DeWitte M, Balkwill F, Gore M. Harrison ML, et al. Among authors: dewitte m. J Clin Oncol. 2007 Oct 10;25(29):4542-9. doi: 10.1200/JCO.2007.11.2136. J Clin Oncol. 2007. PMID: 17925549 Clinical Trial.
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, Sprague E, DeWitte M, Martino HK, Erickson J, Pandite L, Russo M, Lambert JM, Howard M, Ratain MJ. Helft PR, et al. Among authors: dewitte m. Clin Cancer Res. 2004 Jul 1;10(13):4363-8. doi: 10.1158/1078-0432.CCR-04-0088. Clin Cancer Res. 2004. PMID: 15240523 Clinical Trial.
A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer.
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE, Vora R, Prabhakar U, Nakada M, Corringham RE, DeWitte M, Sturgeon C, Propper D, Balkwill FR, Smyth JF. Brown ER, et al. Among authors: dewitte m. Ann Oncol. 2008 Jul;19(7):1340-1346. doi: 10.1093/annonc/mdn054. Epub 2008 Mar 5. Ann Oncol. 2008. PMID: 18325912 Free article. Clinical Trial.
A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.
Wiedenmann B, Malfertheiner P, Friess H, Ritch P, Arseneau J, Mantovani G, Caprioni F, Van Cutsem E, Richel D, DeWitte M, Qi M, Robinson D Jr, Zhong B, De Boer C, Lu JD, Prabhakar U, Corringham R, Von Hoff D. Wiedenmann B, et al. Among authors: dewitte m. J Support Oncol. 2008 Jan;6(1):18-25. J Support Oncol. 2008. PMID: 18257397 Clinical Trial.
104 results